Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis

Gastrointestinal symptoms are commonly reported in as much as 65% of people with CF even independent of pancreatic enzyme replacement therapy (PERT) and the most frequent of these symptoms are bloating/distension, flatulence, abdominal pain and bowel habit changes. An alteration in the intestinal microbiome due to intestinal dysmotility, inflammation or other changes including pH changes in the intestine related to CFTR gene mutation may cause intestinal dysbiosis leading to a bacterial overgrowth in the proximal small intestine which may explain some of the findings of distension and bloating in CF.

Our small pilot study aims to investigate use of the only FDA-approved antibiotic, rifaximin for a GI syndrome- IBS, to treat bloating and global GI symptoms in CF patients with bloating and distension. Our goal is to recruit patients >12 years and age/sex matched into rifaximin and placebo arms with total of 100 recruited subjects recruited.

Study Overview

• Status: Not yet recruiting
• Conditions: Abdominal Pain; Cystic Fibrosis; Small Bowel Disease
• Intervention / Treatment: Drug: Rifaximin 550 MG Oral Tablet [XIFAXAN]; Drug: Placebo

Detailed Description

Gastrointestinal symptoms are commonly reported in persons with cystic fibrosis-both adults and pediatrics- and these symptoms cause distress, impact patients quality of life, and can lead to poor nutrition. One of the findings from our largest US study of patient-reported GI symptom outcomes in CF called GALAXY, which enrolled 402 adults and children with CF, was the finding of high rates of patient dissatisfaction with current GI treatments as well as commonly reported symptoms of bloating (48%), fullness (67%) with meals and abdominal distension (50%). This study aims to evaluate if this same-nonsystemically absorbed and noninvasive antibiotic can be used to treat similar commonly reported symptoms in people with CF.

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Phase 2; Phase 3

Contacts and Locations

• Study Contact: Name: Baha Moshiree, MD; Phone Number: 704-355-0244; Email: bmoshire@wakehealth.edu
• Study Contact Backup: Name: Jamie Crawford, BSN; Phone Number: 704-355-0282; Email: jamie.crawford@atriumhealth.org

Study Locations

• United States
  • North Carolina
    • Charlotte, North Carolina, United States, 28204
      • Atrium Health
      • Contact: Jamie Crawford, BSN; Phone Number: 704-355-0282; Email: jamie.crawford@atriumhealth.org
      • Contact: Katelyn Glen, BS; Phone Number: 704.355.0282; Email: katelyn.glen@atriumhealth.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Confirmed CF diagnosis who are enrolled in the CFF registry.
2. Mild to severe symptom severity defined as abdominal Distention score ≥ 2 and/or bloating score ≥ 2 on a Likert Scale of 0-6)
3. Patient age ≥12 years and ≥ 30 kilograms (~66.15 lbs)
4. Ability to provide informed consent or presence of legally authorized representative (LAR)
5. Ability to take drug or placebo by mouth (Pill must be intact. May not be opened, crushed, or modified to aid in ingestion)

Exclusion Criteria:

1. Subjects who have previously been allergic to rifaximin or had a hypersensitivity to rifamycin or used rifaximin for any reason within three months (12 weeks) of the study start date
2. Subjects with FEV1 < 40 (as measured within the last 12 months) will be excluded from the study given potential risks in subjects with advanced lung disease
3. Subjects who have received a new antibiotic for treatment of an acute pulmonary infection, or antibiotics for any other infection within 4 weeks prior to randomization or during the study period. Cyclic Antibiotics- Inhaled cyclic antibiotics are allowed at any timepoint. Oral or systemic cyclic antibiotics are exclusionary except for prophylactic antibiotics (e.g., azithromycin) which are allowed. New prophylactic antibiotics cannot be started within 4 weeks of randomization.
4. Subjects with a recent pulmonary exacerbation defined as 4 weeks prior to screening will not be enrolled
5. Subjects who are on probiotics will be asked to discontinue the use of probiotics 14 days prior to randomization as probiotics can alter the gut microbiome and cause bloating
6. Subjects with newly initiated cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatments within one month prior to the study
7. Subjects with new onset of distal intestinal obstruction syndrome (DIOS) or constipation

8. Subjects with advanced liver disease defined by:

   • portal hypertension and/or child Pugh B or C cirrhosis
   • or those with elevated liver enzymes-both AST/ALT > 3 times the upper limit of normal at screening
9. Subjects with bilirubin or alkaline phosphatase elevations > 2 times the upper limit of normal at screening will be excluded as this may be related to CFTR modulator use
10. Women of childbearing potential who are pregnant, trying to become pregnant, breastfeeding, or not using an acceptable method of contraception as described in Section 6.2.
11. Known clostridium difficile colitis. Colonization with c. difficile is not exclusionary.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment; Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.	Drug: Rifaximin 550 MG Oral Tablet [XIFAXAN]; Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.
Placebo Comparator: Placebo; Participants in this arm will receive placebo three times daily for 14 days.	Drug: Placebo; Participants in this arm will receive placebo three times daily for 14 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rifaximin Treatment Group Improvement of Symptoms	The primary aim and outcome of our study is to show a significant improvement in individual symptoms of abdominal bloating and/or distension, in PwCF (People with Cystic Fibrosis) treated with rifaximin as compared to placebo	Two weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improved ePROS scores	Our secondary aim and outcome will be based on improvements in the overall ePROS scores and sub-scores for bloating and distension as obtained from GALAXY. These questionnaires will be on a Likert scale ranging from 0-6 where 0 is "Not at all" and 6 is "A very great deal"	42 days

Collaborators and Investigators

• Sponsor: Wake Forest University Health Sciences
• Collaborators: University of Minnesota; Nationwide Children's Hospital; University of Texas Southwestern Medical Center
• Investigators: Principal Investigator: Baha Moshiree, MD, Wake Forest University Health Sciences

Publications and helpful links

General Publications

• Furnari M, De Alessandri A, Cresta F, Haupt M, Bassi M, Calvi A, Haupt R, Bodini G, Ahmed I, Bagnasco F, Giannini EG, Casciaro R. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. J Gastroenterol. 2019 Mar;54(3):261-270. doi: 10.1007/s00535-018-1509-4. Epub 2018 Sep 19.

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2024
• Primary Completion (Estimated): June 1, 2024
• Study Completion (Estimated): June 1, 2024

Study Registration Dates

• First Submitted: June 2, 2022
• First Submitted That Met QC Criteria: June 2, 2022
• First Posted (Actual): June 7, 2022

Study Record Updates

• Last Update Posted (Actual): January 30, 2024
• Last Update Submitted That Met QC Criteria: January 29, 2024
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: Cystic Fibrosis; Abdominal pain; Bloating; Rifaximin; Abdominal distension; Cystic Fibrosis in Children; Small intestinal bacterial overgrowth; Intestinal Dysbiosis; People with Cystic Fibrosis
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Pain; Neurologic Manifestations; Signs and Symptoms, Digestive; Infant, Newborn, Diseases; Genetic Diseases, Inborn; Pancreatic Diseases; Fibrosis; Abdominal Pain; Cystic Fibrosis; Anti-Infective Agents; Gastrointestinal Agents; Anti-Bacterial Agents; Rifaximin
• Other Study ID Numbers: IRB00086338; MOSHIR21-A0-I (Other Identifier: Atrium Health)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No